trending Market Intelligence /marketintelligence/en/news-insights/trending/66PZkES4JuPPFnCihxfQpg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Apellis Pharmaceuticals prices $351.5M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Apellis Pharmaceuticals prices $351.5M common stock offering

Apellis Pharmaceuticals Inc. priced its offering of 9.5 million common shares at $37 per share.

The Waltham, Mass.-based biopharmaceutical company also granted underwriters a 30-day option to buy up to an additional 1,425,000 common shares at the same price.

Gross proceeds are expected to be about $351.5 million.

Citigroup, J.P. Morgan and Evercore ISI are acting as joint book-running managers for the offering, while Cantor Fitzgerald & Co. and Baird are acting as lead managers.

Apellis develops therapies through the inhibition of the complement system for autoimmune and inflammatory diseases. In Jan. 7, the company said a late-stage study showed that its drug APL-2 increased hemoglobin protein in patients with paroxysmal nocturnal hemoglobinuria — a rare life-threatening disease that destroys red blood cells during a late-stage study.